Conversely, the knowledge that half
of the women who discontinue antidepressant
treatment proximate to conception
do not relapse early in pregnancy
might prompt others to pursue
medication discontinuation to avoid
prenatal exposure during a critical period
of organogenesis such as the first
12 weeks of gestation. It is noteworthy
that as some of these patients might
reintroduce antidepressant therapy in
the second trimester, our data (Figure)
suggest that reintroduction of antidepressant
therapy during pregnancy attenuated
risk of depressive relapse, but
not entirely